GT Biopharma, Inc.: Reduced quorum requirement for stockholder meetings from a majority to not less than one-third of outstanding shares entitled to vote (effective 2026-06-08).
“On June 8, 2026, the Board of Directors (the “Board”) of GT Biopharma, Inc., a Delaware corporation (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws, effective June 8, 2026, to reduce the number of shares that are required to be present in person or by proxy at a meeting of the Company’s stockholders (a “Meeting”) for purposes of establishing a quorum.”
Listing & Compliance Notices
GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(H)).
“May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that”
Material Agreements
GT Biopharma, Inc. entered into Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota valued at up to approximately $3.8 million (effective 2026-04-03).
“On April 3, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), entered into an Investigator Initiated Clinical Trial Agreement (the “Agreement”) with the Regents of the University of Minnesota (the “University”), pursuant to which, the University shall sponsor an Investigational New Drug (“IND”) application for IND 169118 GTB-5550 (the “Research Program”) and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, “GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy,” designed by University (the “Study”).”
Auditor Changes
GT Biopharma, Inc. reported that prior financial statements should not be relied upon.
“on March 1, 2026, the audit committee of the Company’s board of directors, after discussion with the Company’s management and Weinberg, concluded that this resulted in an error in the Company’s interim quarterly financial statements as originally reported in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2025, and September 30, 2025, which may no longer be relied upon.”
Listing & Compliance Notices
GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par value per share (the “Common Stock”) had closed below $1 per share for 30 consecutive business days and, as a result, the Company was not in compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). This Letter has no immed”
Equity Issuances
GT Biopharma, Inc. issued preferred stock to certain of the holders of GT Biopharma, Inc.'s Series L 10% Convertible Preferred Stock.
“each of September 17, 2025, September 18, 2025 and September 23, 2025, certain of the holders of GT Biopharma, Inc.’s Series L 10% Convertible Preferred Stock (the “Series L Preferred Stock”) provided a waiver (the “Waiver”) to the Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock (the “Certificate of Designations”)”
David C. Mun-Gavin was appointed as Non-employee Director and Chair of the Compensation Committee at GT Biopharma, Inc..
“On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.”
Andrew Ritter resigned as Member of the Board of Directors at GT Biopharma, Inc..
“On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.”
Rajesh Shrotriya resigned as Director at GT Biopharma, Inc..
“Rajesh Shrotriya resigned as a member of the Board and all committees thereof.”
Andrew Ritter was appointed as Non-Employee Director at GT Biopharma, Inc..
“appointed Andrew Ritter as a non-employee director to fill one of the vacancies on the Board.”
Bruce Wendel resigned as Director at GT Biopharma, Inc..
“Bruce Wendel resigned as a member of the Board and all committees thereof.”
Hilary Kramer was appointed as Non-Employee Director at GT Biopharma, Inc..
“appointed Hilary Kramer as a non-employee director to fill the vacancy created by the increase in the size of the Board”
Michael Breen was appointed as Chief Executive Officer at GT Biopharma, Inc..
“On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.”
Dr. Jeffrey Miller changed role as Consulting Senior Medical Director at GT Biopharma, Inc..
“Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.”
Alan L. Urban was appointed as Chief Financial Officer at GT Biopharma, Inc..
“In connection with Mr. Ohri’s termination, on June 3, 2024, the Company has appointed Alan L. Urban as the Company’s Chief Financial Officer.”
Manu Ohri was terminated as Chief Financial Officer at GT Biopharma, Inc..
“On June 3, 2024, Manu Ohri’s employment as Chief Financial Officer at GT Biopharma, Inc. (the “Company”) was terminated.”
Material Agreements
GT Biopharma, Inc. amended Amendment No. 1 to Settlement and Investment Agreement with Cytovance Biologics, Inc. (effective 2024-04-25).
“On April 25, 2024, the Registrant entered into Amendment No. 1 to Settlement and Investment Agreement (the “Amendment”) with Cytovance to increase the limit on Cytovance’s ownership of shares of the Registrant’s common stock from 4.9% to 9.9% of the outstanding shares of the Registrant’s common stock.”
Governance Changes
GT Biopharma, Inc.: Filed Certificate of Amendment to effect a 1-for-30 reverse stock split of common stock, effective February 2, 2024, with reduced outstanding shares and unchanged authorized shares (effective 2024-02-02).
“On February 1, 2024, GT Biopharma, Inc. filed a Certificate of Amendment of our Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of our common stock, par value $0.001 per share, at a ratio of 1-for-30.”
Shareholder Votes
GT Biopharma, Inc. shareholders approved Reverse stock split at ratio between 1-for-5 to 1-for-30 at the 2023-12-18 meeting.
“Proposal to approve an amendment to the Registrant’s second restated certificate of incorporation, as amended, to effect a reverse stock split with respect to the Registrant’s issued and outstanding common stock, par value $0.001 per share, at a ratio between 1-for-5 to 1-for-30, or the Range, with the ratio within such Range to be determined at the discretion of the Board without further approval or authorization of the Registrant’s stockholders and included in a public announcement.”
Listing & Compliance Notices
GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“August 22, 2023, GT Biopharma, Inc. (the “Company”) received notice from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) advising that the Staff determined the Company is eligible for an additional 180 calendar day period, or until February 20, 2024, to regain compliance with its minimum bid price requirement rule under Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) pursuant to the Nasdaq Listing Rule 5810(c)(3)(A). The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continu”
Shareholder Votes
GT Biopharma, Inc. shareholders approved Non-binding advisory vote endorsing the Registrant's executive compensation at the 2023-06-28 meeting.
“For Against Abstain Broker Non-Votes 8,916,400 2,034,860 13,805 9,736,535”
Shareholder Votes
GT Biopharma, Inc. shareholders approved Ratification of the appointment of Weinberg & Company, P.A. as the Registrant's independent accountants for the year ending December 31, 2023 at the 2023-06-28 meeting.
“For Against Abstain 19,823,634 849,463 28,503”
Shareholder Votes
GT Biopharma, Inc. shareholders approved Election of four members of the Board of Directors at the 2023-06-28 meeting.
“Director For Withheld Michael Breen 9,817,096 1,147,969 Rajesh Shrotriya, M.D. 9,728,749 1,236,316 Bruce Wendel 7,757,208 3,207,857 Charles J. Casamento 9,266,209 1,698,856”
Charles J. Casamento was appointed as Director at GT Biopharma, Inc..
“the Registrant’s Board appointed Charles J. Casamento to fill a vacant seat on the Board”
Alan Urban resigned as Director at GT Biopharma, Inc..
“On May 1, 2023 Alan Urban resigned as a member of the Registrant’s Board of Directors (the “Board”).”
Listing & Compliance Notices
GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 22, 2023, GT Biopharma, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock”
Gregory Berk departed as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..
“Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.”
Governance Changes
GT Biopharma, Inc.: Amended and restated bylaws to update procedures, including shareholder meetings, advance notice requirements, proxy access, and exclusive forum provision (effective 2022-11-03).
“On November 3, 2022, the Board of Directors of GT Biopharma, Inc. (the “Company”) amended and restated the Company’s Restated Bylaws (the “Amended Bylaws”) to update certain procedures and make various technical and conforming changes.”
Alan L. Urban was appointed as Director at GT Biopharma, Inc..
“Effective June 9, 2022, pursuant to the authority granted under the Registrant’s Amended and Restated Bylaws, the Registrant’s Board of Directors (“Board”) appointed Alan L. Urban to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board.”
Gregory Berk changed role as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..
“Gregory Berk, M.D. ceased serving as the Registrant’s Interim Chief Executive Officer, but will continue to serve as the Registrant’s President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.”
Michael Breen was appointed as Interim Chief Executive Officer at GT Biopharma, Inc..
“Effective March 2, 2022, the Registrant appointed Michael Breen as the Registrant’s Interim Chief Executive Officer with an increase in his annual base compensation to $515,000.”
Gavin Choy departed as Acting Chief Financial Officer at GT Biopharma, Inc..
“Gavin Choy ceased serving as the Registrant’s Acting Chief Financial Officer.”
Manu Ohri was appointed as Chief Financial Officer at GT Biopharma, Inc..
“Effective February 14, 2022, the Registrant appointed Manu Ohri as the Registrant’s Chief Financial Officer”
Anthony Cataldo resigned as Director at GT Biopharma, Inc..
“On December 15, 2021, Anthony Cataldo resigned as a member of the Registrant’s Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.